Rare Skin Cancers: Diagnosis, Margin Control, and Treatment — A Living Review

Scope and Clinical Thesis

Rare primary cutaneous malignancies are a test of sequence. The sequence is diagnosis, biologic risk, staging, margin strategy, additional therapy, then reconstruction and surveillance. Reversing that order can turn a manageable tumor into a second operation, erase a sentinel-node opportunity, or apply the wrong evidence to the wrong disease.

This review covers dermatofibrosarcoma protuberans (DFSP), atypical fibroxanthoma (AFX), pleomorphic dermal sarcoma (PDS), extramammary Paget disease (EMPD), sebaceous carcinoma, microcystic adnexal carcinoma (MAC), selected adnexal and sweat-gland carcinomas, Merkel cell carcinoma (MCC), and a bounded set of other cutaneous sarcomas. The goal is not to build a miniature encyclopedia. It is to protect the treatment decisions that transfer poorly between diagnoses.

The Pathology Name Is the First Treatment Decision

The same pink nodule can represent AFX, PDS, poorly differentiated squamous cell carcinoma, spindle-cell melanoma, MCC, sebaceous carcinoma, or a metastasis. The same eczematous plaque can represent EMPD, melanoma in situ, squamous intraepithelial disease, or an inflammatory rash. The same firm scar-like plaque can represent DFSP, MAC, morphea, or a benign process.

Confirm the exact dermatopathologic diagnosis before choosing a margin or procedure: rare tumors can follow different surgical, staging, radiation, or systemic-treatment pathways.

Biopsy depth and specimen design

A superficial specimen may establish that a tumor is malignant yet miss the feature that tells the team which malignancy it is. DFSP and MAC often require subcutis in the specimen. AFX cannot be securely separated from PDS unless the deeper interface and adverse features are evaluated. Periocular sebaceous carcinoma may require assessment for pagetoid conjunctival spread. EMPD may need directed sampling of an ill-defined field and an immunohistochemical panel that addresses primary versus secondary disease.^{1,8,9,13–16}

Immunohistochemistry and molecular testing

CD34 supports DFSP in the right morphologic context, while COL1A1::PDGFB testing can confirm difficult cases and inform selected imatinib use.^1,4 CK7 can highlight EMPD cells, but it does not independently establish primary EMPD or define every margin.^9,12–14 Adipophilin and androgen-receptor staining can support sebaceous differentiation. Cytokeratin 20 in a perinuclear-dot pattern, neuroendocrine markers, and Merkel cell polyomavirus-related testing can support MCC, but the differential still includes another neuroendocrine carcinoma.^19,20

Mismatch-repair testing is not a ritual for every sebaceous neoplasm. It becomes important when the carcinoma, age, multiplicity, personal history, or family history raises concern for Muir-Torre/Lynch syndrome.²⁷

When to request a dermatopathology second opinion

A second review is high-yield when it could change any of the following:

• AFX versus PDS.
• DFSP versus dermatofibroma, spindle-cell tumor, or fibrosarcomatous DFSP.
• Primary versus secondary EMPD.
• Sebaceous carcinoma versus squamous or another adnexal carcinoma.
• MAC versus benign adnexal proliferation, desmoplastic trichoepithelioma, or morpheaform carcinoma.
• MCC versus another cutaneous neuroendocrine malignancy.

The value is not ceremonial agreement. It is prevention of a different operation, scan, nodal procedure, radiation plan, or drug pathway being built on the wrong name.

Margin Control Is a Method, Not a Diagnosis

Mohs micrographic surgery and complete circumferential peripheral and deep margin assessment (CCPDMA) examine the outer and deep surgical boundary more completely than representative bread-loaf sections. That advantage matters most when a tumor has asymmetric subclinical extension, lies in functionally sensitive anatomy, and can be recognized reliably with the selected processing method.

Margin control has three nonnegotiable limits:

1. The central tumor still needs permanent evaluation. A margin layer cannot replace review of depth, invasion, necrosis, lymphovascular or perineural growth, or other staging features.
2. Processing must fit the tumor. Some diagnoses are readily recognized on routine frozen sections; others are safer with permanent-section staged excision or validated immunostains.
3. A clear skin edge is not complete cancer care. MCC nodal staging, EMPD associated-malignancy evaluation, PDS imaging, or sarcoma systemic planning can remain necessary after local clearance.

The memorable rule is: map the edge when the edge is the problem; widen the team when biology is the problem.

Dermatofibrosarcoma Protuberans

DFSP is a dermal fibroblastic sarcoma that commonly infiltrates subcutaneous fat in thin, irregular projections. Its visible plaque or nodule can understate its true footprint. Ordinary DFSP is usually more locally aggressive than metastatic; fibrosarcomatous transformation changes that risk profile.^1,4

Diagnosis

A deep biopsy should show the dermal spindle-cell proliferation and its relationship to fat. CD34 and fusion testing support difficult cases, especially when morphology is altered by recurrence or fibrosarcomatous change.^1,4

Local treatment

The updated European guideline prefers micrographically controlled surgery for localized DFSP. A 2022 meta-analysis found low observed recurrence after Mohs, while conventional excision with roughly 2-3 cm margins remains a supported alternative when micrographic surgery is unavailable or when depth and anatomy require another oncologic operation.^1,2

A 2022 meta-analysis reported pooled local recurrence of 1.5% after Mohs and 9.4% after wide local excision.² These were not randomized groups; referral patterns, processing, center expertise, and follow-up differed. The result supports the margin-control principle without proving that Mohs alone caused every difference.

Tissue preservation is clinically meaningful. In 74 primary cases, Mohs was estimated to preserve about 49% more skin than a modeled 2-cm margin and 68% more than a modeled 3-cm margin.³ That advantage matters on the face, hands, genital skin, and other constrained sites, but it never justifies leaving an inadequately assessed deep margin.

When DFSP becomes a sarcoma-team problem

Fibrosarcomatous transformation, repeated recurrence, large size, deep fixation, fascia or muscle involvement, or unresectable disease warrants broader staging and multidisciplinary planning. MRI or other cross-sectional imaging can define deep extent. Radiation may enter when margins cannot be cleared or recurrence risk remains high. Imatinib can fit selected PDGFB-driven unresectable, recurrent, metastatic, or neoadjuvant settings.^1,4

The AFX-PDS Boundary

AFX and PDS are not interchangeable synonyms. AFX is confined to the dermis and lacks subcutaneous invasion, tumor necrosis, and lymphovascular or perineural invasion. Finding one of those adverse features moves the diagnosis toward PDS and changes the expected metastatic risk and surveillance.^7,8

This boundary explains why the complete central tumor must be reviewed on permanent sections even when a margin-controlled operation is used. A shave biopsy can correctly identify a pleomorphic spindle-cell malignancy yet be too shallow to assign the final category.

A 2018 meta-analysis reported AFX recurrence of 2.0% after Mohs and 8.7% after wide excision, but the underlying studies were low quality and used variable definitions.⁵ A later individual-participant meta-analysis did not find a procedure difference and estimated recurrence or progression risk below 1% after two years.⁶ These apparently discordant findings are a lesson in rarity, classification drift, and selection bias.

The more contemporary nationwide Danish cohort provides the clearest risk contrast: at five years, local recurrence was 10% for AFX and 17% for PDS; metastasis was 0.8% and 16%, respectively. More than 90% of PDS metastases occurred within three years, most often to lung.⁷

For a true AFX, margin-controlled surgery is a reasonable tissue-sparing local approach. For PDS, local clearance is necessary but not sufficient; depth, adverse pathology, imaging, radiation, sarcoma input, and structured surveillance become more prominent.

Extramammary Paget Disease

EMPD often presents as a persistent eczematous plaque in genital, perineal, perianal, groin, or axillary skin. The first diagnostic fork is not simply "Paget or not." It is primary or secondary, intraepidermal or invasive, localized or field-spreading, and associated malignancy present or absent.^9,13,14

Primary versus secondary disease

Pathology, site, and directed immunohistochemistry help distinguish a primary cutaneous process from pagetoid spread related to colorectal, urothelial, gynecologic, or another nearby malignancy. The evidence-based guideline recommends age-, site-, and sex-appropriate evaluation rather than the same indiscriminate testing for every patient.⁹

Local treatment

EMPD can extend beyond the visible erythema and into adnexal structures. A meta-analysis reported pooled local recurrence of 7.3% after Mohs and 26.3% after wide excision.¹⁰ A prospective observational female-genital study reported three-year recurrence-free survival of 93.3% with Mohs-guided excision versus 65.9% with traditional excision.¹¹ Both support early margin-control consideration, particularly near the urethra, clitoris, vagina, anus, scrotum, or penis, but neither is a randomized comparison.

CK7 can improve intraoperative visibility. In a multicenter series of 61 tumors treated with Mohs plus CK7, recurrence was 3.3% at a mean 43.5 months.¹² The stain is a tool, not a verdict; normal anogenital structures and secondary disease can complicate interpretation.

Topical imiquimod, radiation, and other nonsurgical options can fit selected superficial, multifocal, medically inoperable, function-threatening, recurrent, or unresectable disease. A clinical response should not be assumed to equal histologic clearance. Invasive or node-positive disease belongs in a multidisciplinary pathway.^9,14

Sebaceous Carcinoma

Sebaceous carcinoma may be periocular or extraocular. Periocular disease raises distinct concerns: pagetoid spread into conjunctival epithelium, orbital anatomy, regional nodes, visual function, and the need for ophthalmic or ocular-oncology coordination.^16,24

The 2024 S1 guideline recommends complete microscopically controlled surgery as first-line local treatment for both periocular and extraocular disease, with conventional excision when full margin control is not available.¹⁶ A systematic review supports the margin-control rationale but remains limited by retrospective selection and inconsistent follow-up.¹⁷

Regional-node assessment, imaging, sentinel-node discussion, radiation, and systemic therapy should be individualized for larger, recurrent, poorly differentiated, invasive, or clinically node-suspicious tumors. The guideline reports nodal metastasis up to 15% for periocular and up to 2% for extraocular disease, but these are heterogeneous estimates rather than personal predictions.¹⁶

The hereditary question belongs beside the surgical question. A sebaceous carcinoma can be the clue that uncovers Muir-Torre/Lynch syndrome; tumor testing and genetic evaluation are appropriate when the clinical and family context supports them.

Microcystic Adnexal Carcinoma

MAC is a deeply infiltrative adnexal carcinoma with a tendency for perineural growth and subclinical extension. A superficial biopsy can sample bland superficial ducts while missing the deeper infiltrative component.

The evidence-based guideline was informed by 55 studies containing 1,968 patients. It recommends a biopsy including subcutis and, for skin-confined disease, Mohs or CCPDMA. It also recommends clinician follow-up every 6-12 months for the first five years.¹⁵ There were no controlled treatment trials; certainty comes from consistent clinicopathologic behavior and retrospective evidence.

Perineural symptoms, large size, recurrence, deep fixation, or extension toward orbit, skull base, or major nerves may require MRI, staged permanent sections, wider/deeper resection, and radiation discussion. The apparently bland microscope does not make MAC a trivial tumor.

Other Adnexal and Sweat-Gland Carcinomas

"Adnexal carcinoma" is an incomplete management label. Eccrine porocarcinoma, hidradenocarcinoma, digital papillary adenocarcinoma, primary cutaneous mucinous carcinoma, pilomatrix carcinoma, spiradenocarcinoma, and related tumors differ in regional-node risk, distant spread, recurrence, and available systemic options.¹⁸

Mohs series provide useful local-control signals for several subtypes, but cohorts are small and selected. The safe approach is to resolve the exact entity, depth, grade, lymphovascular or perineural invasion, margins, and clinical nodal status before deciding whether Mohs, wide excision, sentinel-node evaluation, imaging, radiation, or medical oncology fits.

Do not let the strongest MAC evidence become an umbrella recommendation for all sweat-gland cancers.

Merkel Cell Carcinoma

MCC is the clearest example of why a rare skin cancer cannot be reduced to its surgical edge. It is an aggressive cutaneous neuroendocrine carcinoma with meaningful occult nodal and distant risk.^19,20

Build the skin-and-nodes plan before definitive excision

For clinically node-negative disease, contemporary ESMO-EURACAN and NCCN pathways generally support baseline staging and sentinel lymph-node biopsy when feasible.²⁰ Lymphatic mapping should occur before definitive excision whenever possible because surgery can alter drainage.

Primary size does not identify a zero-risk group. In a 153-patient cohort, sentinel-node positivity was 25% for tumors 2 cm or smaller and 45% above 2 cm.²¹

Local surgery

Wide excision is conventional. Mohs can provide complete margin assessment and tissue preservation for selected primary tumors, particularly in constrained sites. But Mohs is only appropriate when it is embedded in the complete MCC plan: preserve sentinel-node sequencing, send the central tumor for permanent pathology, and coordinate radiation and systemic decisions.^19,20,22

Radiation and systemic therapy

Adjuvant radiation is diagnosis- and risk-specific. Primary site, margins, immune status, nodal findings, anatomy, and treatment morbidity all matter. For unresectable or metastatic MCC, PD-1 or PD-L1 checkpoint therapy is preferred for most eligible patients because responses can be durable.¹⁹

Adjuvant therapy after complete resection remains an evolving area. In ADMEC-O, nivolumab produced disease-free survival of 85% versus 77% at one year and 84% versus 73% at two years. The hazard ratio was 0.58, but its confidence interval crossed 1; overall survival was immature, radiation use was imbalanced, and grade 3-4 adverse events occurred in 42% versus 11%.²³ That is a meaningful discussion signal, not proof of universal benefit.

Other Rare Cutaneous Sarcomas

Cutaneous angiosarcoma and cutaneous leiomyosarcoma belong here as boundary diagnoses, not as compressed subchapters.

Angiosarcoma is often a broad-field, infiltrative, systemically dangerous disease. Imaging, wide-field surgery, radiation, and medical oncology commonly matter more than a narrow margin-control discussion.²⁵

Dermal leiomyosarcoma generally behaves better than subcutaneous disease, but the evidence is sparse and terminology has evolved. Depth, grade, necrosis, mitoses, and margins shape the plan.²⁶

Kaposi sarcoma and primary cutaneous lymphoma require separate hematology/oncology and disease-specific frameworks. They should not be routed into a Mohs-centered rare-tumor pathway merely because they involve skin.

Reconstruction Should Follow the Oncologic Map

Reconstruction is not the final decorative step. It is part of oncologic sequencing. The repair should preserve:

• Permanent evaluation of the central tumor.
• Sentinel-node mapping when indicated.
• Re-excision access if margin status remains uncertain.
• Radiation planning and wound-healing needs.
• Function, surveillance, and future imaging.

For an ill-defined EMPD field, deep DFSP, periocular sebaceous carcinoma, MAC with perineural growth, or MCC awaiting nodal staging, delayed or staged reconstruction may be safer than immediate complex tissue movement. The best repair is the one that follows a sound cancer plan.

A Diagnosis-Specific Team Map